INTRODUCTION
In order to study the regulation of growth hormone (GH) secretion by GH-releasing factor (GRF) it would be extremely useful to identify a simple animal model which is deficient in endogenous GRF, but which could respond to exogenous GRF by secreting GH and showing a growth response in vivo. Current studies have convincingly demonstrated the effectiveness of GRF in vivo, using manipulations which chemically or surgically destroy GRF cells, or block the actions of endogenous GRF (for review, see Guillemin, Brazeau, Bohlen et al. 1984 ). An alternative approach would be to look for genetic mutants which show deficiencies in growth which are attributable to defects in GRF or GH synthesis or secretion. Mutant strains of rats or mice are proving increasingly valuable in endocrine research (Charlton, 1984) and there are several strains which have been shown to have impaired GH secretion associated with poor growth. The Munich-Wistar rat strain was originally reported to secrete GH poorly (Martin, Harris & Dirks, 1974) Clark, unpublished results) . Of the three common strains of growth-deficient mice, the Dwarf and Ames mice show multiple anterior pituitary hormone deficiencies and lack identifiable somato¬ trophs, whereas the 'Little' mouse shows a relatively specific partial defect in GH synthesis and secretion (Cheng, Beamer, Phillips et al. 1983) . Peripheral GH receptors are normal in Little mice (Herington, Harrison & Graystone, 1983) and their growth retardation can be overcome by treatment with GH (Clark & Robinson, 1985a (Fig. 1) . Large GH secretory responses to hGRFl-29NH2 were also seen in normal C57: + / + mice (Fig. 2) , whereas Little mice had much lower basal levels (<0^g/l compared with 62+ 28(mean + s.E.M.) µ §/1 for C57: +/+ normals), and showed virtually no GH response to hGRFl-29NH2 injections (Fig. 2) . In both saline-treated and (1983) showed that anterior pituitary glands of Little mice do contain somatotrophs, but that these cells are deficient in secretory granules, and that the GH precursor RNA and messenger RNA (mRNA) are present but at reduced levels. These findings underlie the observation that pituitary GH levels in these mice are 6-8% of those in hétérozygotes (Cheng et al. 1983 ) and 4% of the normal C57BL controls in our studies. The inability of hGRFl-29NH2 to release GH is not due to species differences in GRF responses, since this analogue proved to be a highly efficient secretagogue in the normal C57: +/+ strain, as well as in Parkes mice. The doses we gave (5 and 100 pg/kg) produced very large GH secretory responses in normal mice and are at or above the maximally effective dose range in rats . It is possible, however, that mouse GRF, or much larger doses of hGRFl-29NH2, might induce a secretory response in Little mice. Basal plasma GH levels in Little mice were mostly undetect¬ able (<0-8 pg/1) as was also reported by Cheng et al. (1983) . The high plasma GH values (20-70 pg/1) reported by others (Herington et al. 1983; Hammer, Palmiter & Brinster, 1984) would not seem consistent with the low pituitary GH content, marked growth deficiency and low somatomedin levels (Nissley, Knazek & Wolff, 1980) When Little mice become pregnant or pseudo¬ pregnant they show both weight gain and increased bone growth. suggested that the mechanism for this might involve a rise in blood GH concentrations via the appearance of a specific GH binding protein, proposed by Peeters & Friesen (1976) (but see Sinha, Baxter & VanderLaan, 1979 (Iddon, Charlton & Fink, 1980; Krieger, Perlow, Gibson et al. 1982 (Hammer et al. 1984) . There is also the possibility that the genetic defect which gives rise to low GH levels and no GRF respon¬ siveness may find a clinical parallel in some short stature children who are recognized as GH deficient and who respond poorly to GRF.
